The histological assessment of liver fibrosis in grafts from extended criteria donors predicts the outcome after liver transplantation: A retrospective study.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
02 2020
Historique:
received: 07 01 2019
revised: 07 04 2019
accepted: 04 05 2019
pubmed: 4 6 2019
medline: 16 12 2020
entrez: 4 6 2019
Statut: ppublish

Résumé

The use of extended criteria donors (ECD) in liver transplantation is increasing due to the organ shortage. Histological evaluation of the liver graft in the context of procurement is an important tool for extending the donor pool without affecting the quality of the transplanted organs. Macrovesicular steatosis is widely accepted as predictor of early allograft dysfunction (EAD), while other features, such as portal fibrosis, are poorly studied. To identify morphological features, other than macrovesicular steatosis, that may affect recipients' outcome. Between 2014 and 2016, 132 donors with extended criteria underwent pre-transplant liver biopsy during procurement. Histological variables of the graft, donors'/recipients' clinical data, EAD and patient/graft survival were registered. The recipients who received a graft with histological-proven portal fibrosis had a significant lower patient and graft survival in comparison to patients without fibrosis (P = 0.044 and P = 0.039, respectively). Donors' dyslipidemia was significantly associated with the occurrence of EAD (P = 0.021). When dyslipidemia was combined with histological liver fibrosis a 54.5% incidence of EAD was observed (P = 0.012). The histological assessment of liver fibrosis in pre-transplant biopsy of ECD grafts, together with donor's clinical data, provides important information on recipients' outcome.

Sections du résumé

BACKGROUND
The use of extended criteria donors (ECD) in liver transplantation is increasing due to the organ shortage. Histological evaluation of the liver graft in the context of procurement is an important tool for extending the donor pool without affecting the quality of the transplanted organs. Macrovesicular steatosis is widely accepted as predictor of early allograft dysfunction (EAD), while other features, such as portal fibrosis, are poorly studied.
AIM
To identify morphological features, other than macrovesicular steatosis, that may affect recipients' outcome.
METHODS
Between 2014 and 2016, 132 donors with extended criteria underwent pre-transplant liver biopsy during procurement. Histological variables of the graft, donors'/recipients' clinical data, EAD and patient/graft survival were registered.
RESULTS
The recipients who received a graft with histological-proven portal fibrosis had a significant lower patient and graft survival in comparison to patients without fibrosis (P = 0.044 and P = 0.039, respectively). Donors' dyslipidemia was significantly associated with the occurrence of EAD (P = 0.021). When dyslipidemia was combined with histological liver fibrosis a 54.5% incidence of EAD was observed (P = 0.012).
CONCLUSIONS
The histological assessment of liver fibrosis in pre-transplant biopsy of ECD grafts, together with donor's clinical data, provides important information on recipients' outcome.

Identifiants

pubmed: 31155489
pii: S1590-8658(19)30592-4
doi: 10.1016/j.dld.2019.05.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

185-189

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Antonia D'Errico (A)

Pathology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy. Electronic address: antonietta.derrico@unibo.it.

Mattia Riefolo (M)

Pathology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Matteo Serenari (M)

General and Transplant Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Vanessa De Pace (V)

General and Transplant Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Giacomo Santandrea (G)

Pathology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Melissa Monica (M)

Pathology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Carlo de Cillia (C)

Regional Transplant Center, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Matteo Ravaioli (M)

General and Transplant Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Matteo Cescon (M)

General and Transplant Surgery Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Francesco Vasuri (F)

Pathology Unit, S.Orsola-Malpighi University Hospital, Bologna, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH